At the time of writing, Organon & Co. [OGN] stock is trading at $18.16, down -1.36%. An important factor to consider is whether the stock is rising or falling in short-term value. The OGN shares have gain 1.40% over the last week, with a monthly amount drifted -0.98%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, April 2024, Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024. In a post published today on Yahoo Finance, Company estimates $15 million of milestone payments in the first quarter.
From an analyst’s perspective:
Organon & Co. [NYSE: OGN] stock has seen the most recent analyst activity on November 03, 2023, when Goldman downgraded its rating to a Neutral and also revised its price target to $16 from $33. Previously, Barclays started tracking the stock with Overweight rating on September 21, 2023, and set its price target to $28. On March 16, 2023, Raymond James initiated with a Outperform rating and assigned a price target of $33 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $25 on October 14, 2022. Piper Sandler upgraded its rating to a Overweight and reduced its price target to $34 on September 06, 2022. BofA Securities downgraded its rating to Neutral for this stock on August 05, 2022, and downed its price target to $37. In a note dated April 27, 2022, Goldman initiated an Buy rating and provided a target price of $40 on this stock.
For the past year, the stock price of Organon & Co. fluctuated between $10.84 and $24.79. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Organon & Co. [NYSE: OGN] shares were valued at $18.16 at the most recent close of the market. An investor can expect a potential return of 87.22% based on the average OGN price forecast.
Analyzing the OGN fundamentals
According to Organon & Co. [NYSE:OGN], the company’s sales were 6.26B for trailing twelve months, which represents an 7.61% jump. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is -2.1 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -125.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.03 points at the first support level, and at 17.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.25, and for the 2nd resistance point, it is at 18.35.
Organon & Co. [OGN] reported earnings per share of $0.88 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.83/share, meaning a difference of $0.05 and a surprise factor of 6.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.87 per share as compared to estimates of $1.06 per share, a difference of -$0.19 representing a surprise of -17.90%.
Ratios To Look Out For
It is important to note that Organon & Co. [NYSE:OGN] has a current ratio of 1.54. On the other hand, the Quick Ratio is 1.09, and the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 0.74 and price to earnings (TTM) ratio is 4.55.
Transactions by insiders
Recent insider trading involved Weaver Kirke, Gen. Counsel & Corp. Secy., that happened on Feb 22 ’24 when 2720.0 shares were purchased.
